Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins

Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins

ABSTRACT The clinical utility of rifamycins against non-tuberculous mycobacterial (NTM) disease is limited by intrinsic drug resistance achieved by ADP-ribosyltransferase Arr. By blocking the site of ribosylation, we recently optimized a series of analogs with substantially improved potency against...

Full description

Bibliographic Details
Main Authors: Uday S. Ganapathy, Tian Lan, Véronique Dartois, Courtney C. Aldrich, Thomas Dick
Format: Article
Language:English
Published: American Society for Microbiology 2023-10-01
Series:Microbiology Spectrum
Subjects:
rifamycins
NTM
non-tuberculous mycobacteria
ADP-ribosylation
M. abscessus
M. chelonae
Online Access:https://journals.asm.org/doi/10.1128/spectrum.01900-23

Internet

https://journals.asm.org/doi/10.1128/spectrum.01900-23

Similar Items